Citi Finds Biotech Executives Jump Ship Ahead of Bad Drug Trials

(Bloomberg) -- Analysis confirms what many on the Street were already thinking: biotech executives leaving ahead of late-stage clinical data often means the study will fail, according to one Citi a...